Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries
Crossref DOI link: https://doi.org/10.1007/s10198-014-0595-3
Published Online: 2014-05-16
Published Print: 2014-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Brodszky, Valentin
Baji, Petra
Balogh, Orsolya
Péntek, Márta
Text and Data Mining valid from 2014-05-01
Version of Record valid from 2014-05-01
Article History
Received: 17 February 2014
Accepted: 31 March 2014
First Online: 16 May 2014